For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .
As a an internal medicine physician, I am often faced with patients who have conditions that result from immune system dysfunctions. These inflammatory or autoimmune diseases are often rare diseases whose causes and symptoms are misunderstood: lupus, myositis autoimmune diseases, immune deficiencies in adults, systemic fibrosis, etc.
Like Marseille Immunopole, our discipline is positioned at the interface of different medical specialties, but also of fundamental and translational research. For many years our service at the Timone Hospital has collaborated with researchers including the ” Natural Killer Cells and Innate Immunity” team of Eric VIVIER at CIML. Together, we have developed a laboratory at the Conception Hospital specializing in the functional exploration of these lymphocytes and rare lymphocyte populations. We are conducting studies to better understand their involvement in diseases such as Systemic Lupus Erythematosus, Immune Thrombocytopenia Purpura (ITP) or IgG4-related diseases. The laboratory has also developed a routine battery of tests to quantify and qualify the activity of NK cells, T helper cells (Th) and Innate Lymphoid Cells (ILCs), particularly in clinical trials.#clinic
By creating this super innovation centre "outside the walls", which is Marseille Immunopole, we leverage our capabilities to ensure better and faster innovation.
With MI-mAbs and other cluster platforms, CIPHE is somewhat the "technology back office" of Marseille Immunopole.
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.
AMU, AP-HM, CIML, INNATE PHARMA
MI should enable us to accelerate discovery, enhance our treatment options and offer more innovative options to our patients through current clinical trials and those of the future.